Real-World data shows Tirabrutinib's promise for rare brain cancer
NCT ID NCT06714370
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 24 adults in Taiwan with a rare brain lymphoma that came back or didn't respond to treatment. Researchers checked how well the drug tirabrutinib worked and what side effects occurred in everyday medical practice, not a strict research lab. The goal was to see how many patients had their tumors shrink or disappear.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chang Gung Memorial Hospital
Kaohsiung City, Taiwan
-
Chang Gung Memorial Hospital
Taoyuan, Taiwan
-
China Medical University Hospital
Taichung, Taiwan
-
National Cheng Kung Univeristy Hospital
Tainan, Taiwan
-
National Taiwan University Hospital
Taipei, Taiwan
-
Taipei Veterans General Hospital
Taipei, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New cocktail of drugs shows promise for deadly brain cancer
- New drug takes aim at Hard-to-Treat blood cancers
- Promising cocktail targets brain cancer
- New hope for brain cancer patients: drug may stop relapse
- New cocktail of three drugs shows promise for tough brain cancer
- New drug takes aim at Hard-to-Treat blood cancers